CORC

在结果中检索

CORC

浏览/检索结果: 共71条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
天琴计划简介 期刊论文
中山大学学报(自然科学版)/Acta Scientiarum Naturalium Universitatis Sunyatseni, 2021, 卷号: 60, 期号: 1-2, 页码: 1-19
作者:  罗俊;  艾凌皓;  艾艳丽;  安子聪;  白伟钢
收藏  |  浏览/下载：138/0  |  提交时间：2021/01/18
一种集气站场用电控撬屏蔽效能测试装置及方法 专利
申请日期: 2020-09-25, 公开日期: 2020-09-25
作者:  高继峰;  麻宏强;  王利畏;  银永明;  陈维国
收藏  |  浏览/下载：9/0  |  提交时间：2020/11/11
Contrasting trends of PM2.5 and surface-ozone concentrations in China from 2013 to 2017 期刊论文
NATIONAL SCIENCE REVIEW, 2020, 卷号: 7, 期号: 8, 页码: 1331-1339
作者:  Wang, Yonghong;  Gao, Wenkang;  Wang, Shuai;  Song, Tao;  Gong, Zhengyu
收藏  |  浏览/下载：30/0  |  提交时间：2021/08/31
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：57/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：45/0  |  提交时间：2019/12/05
Co-loading antioxidant N-acetylcysteine attenuates cytotoxicity of iron oxide nanoparticles in hypoxia/reoxygenation cardiomyocytes 期刊论文
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2019, 卷号: 14
作者:  Shen, Yunli;  Gong, Shiyu;  Li, Jiming;  Wang, Yunkai;  Zhang, Xumin
收藏  |  浏览/下载：26/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：35/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace